Results 121 to 130 of about 49,110 (259)

Microphysiological Systems in Cancer Research: Advancing Immunotherapy through Tumor Microenvironment‐Integrated Organ‐On‐Chip Models

Advanced Therapeutics, EarlyView.
Emerging microphysiological systems reproduce the spatial, biochemical, and cellular complexity of the tumor microenvironment, surpassing 2D cultures and murine models. By integrating patient‐derived tumors, perfusable vasculature, and immune trafficking, these organ‐on‐chip platforms reveal mechanisms of immune evasion, predict therapeutic responses ...
Fabiana Moresi, Francesco Noto, Jyothsna Vasudevan, Xavier Bisteau, Giulia Adriani, Andrea Pavesi   +5 more
wiley   +1 more source

Combination chemotherapy for metastatic colorectal cancer [PDF]

Archive of Oncology, 2003
Koehne Claus-Henning
doaj   +1 more source

Copper and Iron‐Based Metal‐Organic Frameworks for Synergistic Cancer Phototherapies: Recent Advances, Challenges, and Future Prospects

Advanced Therapeutics, EarlyView.
The graphical abstract illustrates the combined effect of PTT and PDT using metal‐organic frameworks (MOFs) in a cancer treatment model. Tumor‐bearing mice are irradiated with different laser lights, which activate the MOF nanoparticles within cancer cells. The MOFs produce reactive oxygen species through PDT, while PTT elevates the temperature to kill
Kayalvizhi Samuvel Muthiah, Kalaiarasu Lakshminarayanan, Yu Chien Lin, Udesh Dhawan, Loganathan Rangasamy, Ren‐Jei Chung   +5 more
wiley   +1 more source

ST6GAL1‐Mediated Sialylation Stabilizes PD‐L1 and Drives Immunosuppressive Tumor Microenvironment in Colorectal Cancer

Advanced Science, EarlyView.
ST6GAL1 plays a critical role in tumor progression and immune regulation in colorectal cancer (CRC). Its depletion significantly suppresses the malignant phenotype of CRC cells and enhances the efficacy of anti‐PD‐L1 therapy. High ST6GAL1 expression promotes an immune‐activated tumor microenvironment (TME), characterized by increased infiltration of ...
Ximo Xu, Jingyi Liu, Wei Qin, Chengsheng Ding, Zhenghao Cai, Duohuo Shu, Hao Zhong, Yanyan Hu, Mengqin Yu, Leqi Zhou, Jianwen Li, Minhua Zheng, Bin Li, Sen Zhang, Xiao Yang, Bo Feng   +15 more
wiley   +1 more source

Tryptophan Metabolite Indole‐3‐Aldehyde Induces AhR and c‐MYC Degradation to Promote Tumor Immunogenicity

Advanced Science, EarlyView.
Tryptophan metabolite Indole‐3‐aldehyde (I3A) downregulates cytosolic AhR and p‐ERK/c‐MYC proteins, together enhancing STAT3 phosphorylation and tumor immunogenicity. Overexpression of the Trp metabolic enzyme interleukin‐4‐induced gene‐1 (IL4I1) in tumor cells increases intracellular levels of I3A and enhances tumor immunogenicity.
Lei Cui, Zining Wang, Zixuan Guo, Hongxia Zhang, Yongxiang Liu, Huanling Zhang, Huan Jin, Feifei Xu, Xiaojuan Wang, Chunyuan Xie, Hui Guo, Tiantian Wang, Yanxun Lin, Qi Zhao, Penghui Zhou, Jing Tan, Jin‐Xin Bei, Peng Huang, Jinyun Liu, Xiaojun Xia   +19 more
wiley   +1 more source

Targeting Cystine Metabolism in the Lung Cancer Environment Enhances the Efficacy of Immune Checkpoint Inhibition

Advanced Science, EarlyView.
The tumor‐associated macrophages (TAMs) in lung cancer tissues exhibit active cystine metabolism. Restricting cystine concentration in macrophages induces M1 phenotypic polarization and upregulation of PD‐L1 expression through the GSH‐NF‐κB signaling pathway.
Yun Xu, Shumin Li, Jiaji Wu, Shumin Xu, Mo Shen, Chenyang Wang, Lundqvist Andreas, Jianghao Yu, Zhiyong Xu, Yueli Shi, Nana Liu, Yunke Yang, Jiangnan Zhao, Ying Yang, Pingli Wang, Peng Yi, Jin Cheng, Junhui Sun, Mengshu Li, Peng Xiao, Kai Wang   +20 more
wiley   +1 more source

Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]

, 1994
Adolf, D., Bergmann, L., Dietzfelbinger, H., Emmerich, B., Knauf, W. U., Langenmayer, Irmgard, Maubach, P. A., Mitrou, P. S., Nerl, C., Thiel, E., Ziegle-Heitbrock, H. W. L.   +10 more
core   +1 more source

A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer

Chinese Journal of Lung Cancer, 2008
Background and objective Docetaxel is an active agent in the second-line treatment for non-small cell lung cancer (NSCLC), many clinical trials have demonstrated that it has similar efficacy to common first-line regimens for NSCLC. A randomized study was
Haiyong WANG, Yanfei GU, Xi LI, Xinjie YANG, Fanbin HU, Qunhui WANG, Shucai ZHANG, Jinghui ZHANG   +7 more
doaj  

The efficacy of niraparib in pediatric recurrent PFA-type ependymoma

Chinese Journal of Contemporary Neurology and Neurosurgery
Objective To investigate the efficacy and safety of the targeted drug poly ADP-ribose polymerase (PARP) inhibitor niraparib combined with low-dose chemotherapy drugs cisplatin and etoposide in the treatment of pediatric recurrent PFA-type ependymoma ...
YU Jian-zhong, HAN Ji-chang, LIU Ya-chao, LI Lin, LI Hao   +4 more
doaj   +1 more source

The LDH‐H3K18La‐Nur77 Axis Potentiates Immune Escape in Small Cell Lung Cancer

Advanced Science, EarlyView.
Lactate from SCLC tumors induces H3K18 lactylation in naïve CD8+ T cells, upregulating Nurr77 and enhancing tonic TCR signaling. This leads to T cell hyporesponsiveness to stimulation, impairing antitumor immunity and reducing immunotherapy efficacy.
Xiaoling Shang, Bo Cheng, Chenyue Zhang, Chenglong Zhao, Ruiqing Wang, Xun Zhang, Dizhi Jiang, Xinyu Zhang, Xinyue Ma, Hongyuan Mao, Zerun Li, Chenhan Huang, Tianzi Wang, Kaiyue Guo, Liwen Wang, Ning Tang, Haiyong Wang   +16 more
wiley   +1 more source